EMEA Cancer Biological Therapy Market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Forecast to 2030

Europe, the Middle East, and Africa Cancer Biological Therapy Market Overview:

The EMEA Cancer biological therapy market is anticipated to reach USD 12,243.4 Million by 2030 at 7.4% CAGR during the forecast period 2022-2030. Cancer is ranked the world’s second most lethal disease caused due to abnormal cell growth that spreads across the human body. Most of the vital and visible signs of cancer are hair loss, weight loss, bleeding in internal organs, benign tumors, lumps in the body, and changes in digestion, and improper bowel movement. There are more than 100 types of cancer known to humans. Major causes of cancer in humans are excessive use of tobacco, no or minimal physical activity, high sugar intake, excessive smoking and drinking, high junk food intake, and other infections like hepatitis B and C.

Most individuals inherit cancer is caused because of mutation of genes. Stage and type of cancer are the deciding factors if the patient could survive the illness or not. Proper screening, ration therapy, chemotherapy, surgery, and maintaining a proper lifestyle are the only start of cancer treatment. Progressive screening and treatment and clearer PET scans give a cancer patient an ideal life survival up to 10 years of the first sign of cancer. The overall health of the patient is degraded to a greater extent. Many healthcare centers have invested in cancer clinics and hospitals to develop hypotheses and models to have a better understanding of the disease. It is reported by WHO that more than 18 million new cancer cases are registered annually with an investment of more than 1.6 trillion US dollars per year.

COVID-19 Analysis:

The global prevalence of COVID-19 since the November of 2019 has held down the world economically, socially, and politically. The world suffered major losses in terms of manpower, local business, corporates, etc. The countries around the globe went into complete lockdown to contain the virus in local areas. Travel and communication were completely restricted due to the fear of the virus and the effect and cure unknown to mankind. People suffering from cancer had adverse effects and, in few cases, it led to life loss. The government, charity, and private funds which were the source of cancer research were depleted due to loss in business and limited money to globally feed the public during the pandemic. Although the study in cancer research did not come to a stand-still any new venture was not made during the time of the pandemic. Slowly, as the world is coming back on its feet, healthcare centers have seen a rise in public and private investors to aid the study and research of cancer.

Europe, the Middle East, and Africa Cancer Biological Therapy Market Dynamics:

Drivers:

With more than 18 million new cancer cases are registered annually with an investment of more than 1.6 trillion US dollars per year as recorded in 2016, the EMEA Cancer biological therapy market has seen a high in research and development area in recent years. The healthcare centers around the world have come up with patient assistance programs (PAPs) with the government’s health to create awareness about the type and stages of cancer. With more than 15% of children under cancer, radar has healthcare centers across the world invest more in NICU cancer departments. There are more than 100 types of cancer known to mankind but few of the major cancers include lung, breast, blood, gastric, colorectal, esophageal, and pancreatic which not only affect the major organs but also decrease the lifespan of humans.

Opportunities:

The Europe, the Middle East, and Africa cancer biological therapy market is all set to witness growth because of the rising cancer incidences among the geriatric populations on a global level. People who are aged above 50 years are more vulnerable and have high chances of developing cancer cells in the body. The statistics released by the World Cancer Research Fund show that by the beginning of the forecast year of 2018, there were approximately 18 million cases of cancer from different corners of the globe. By the end of the same forecast year, there was a 12.3% growth in the cases, worldwide.

The biological therapies and techniques used help in enhancing the immune system and help in the development of better technologies that are playing a major role in helping people to recover at a fast rate.

Technology Analysis:

Cancer biological therapy is rapidly growing due to a greater number of investors interested in funding the research and development department of cancer therapy. Cancer biological therapy deals with injecting drugs in humans on cancer-infected areas to decrease the growth of the tumor or performing radiation-based therapy to the infected areas to diminish the growth. In certain cancers like breast cancer, lung cancer, gynecologic cancer, etc. infected body parts can also be cut out as it is a proven fact that cancer doesn’t eventually get cured it needs to be treated time again depending on the progression and regular PET scans results. Cancer biological therapy around the world has been studied to analyze the cancer type and factors leading to its growth. This analysis had led the government and private sectors to study the market-growth in cancer study and invest accordingly.

Segment Overview:

By Type:

EMEA Cancer biological therapy market is segmented by type as the different type of cancers known to humans like breast cancer, lungs cancer, blood cancer, prostate cancer, gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, etc. and the different type of therapies used to treat them depending on stage and type like targeted therapy, radiation, cancer growth inhibitors, antibodies, interleukins, vaccines, interferons, colony-stimulating factors and treatments, gene therapy, etc.

By Vertical:

EMEA Cancer biological therapy market is segmented by vertical as medical centers, clinical trial hospitals, and healthcare centers, laboratories, and cancer-related research and development centers. Few of these centers are funded by the government and the others by private investors depending on the revenue and growth of these centers.

Regional Analysis:

North America is the current leader of the world’s cancer therapy market due to the high investments done in the research and development center of the cancer department leading to the adaption of cancer therapies. Europe is dominant in the EMEA region of the EMEA Cancer biological therapy market with an expectation of a market rise to more than 20,000 million US dollars by the year 2021. The European EMEA region market of EMEA Cancer biological therapy industry Research forecasts a CAGR of 5.2% by the year 2021. Asia-Pacific countries like China, Japan, and India have also contributed to the increasing Cancer biological therapy industry and are estimated to continue to grow in upcoming years. Middle East (Oman, Kuwait, UAE, Qatar, Bahrain, and Saudi Arabia) is likely to see a CAGR of 4.3% by 2021 with an estimated revenue of more than 6000 million US dollars.

Competitive Landscape:

The EMEA Cancer biological therapy market is on the global rise due to an alarming rate at which cancer patients are increasing. To be prepared and composed for this increasing number of patients is on the priority of many healthcare departments overall the globe. Public and private sectors have been funded seeing to the expansion of cancer patients and related centers for it. Few of the key market players in the EMEA Cancer biological therapy market are Bayer AG, Novartis AG, Johnson and Johnson, Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca plc., Celgene Corporation, Engeneic Ltd., Eli Lily and Company, Merck and Co., Hoffmann-La Roche Ag., Teva Pharmaceutical, and many more.

Recent Developments:

In January 2020, a biopharmaceutical company called ArQule Inc joined hands with Merck and Co. to study the growth and development of a device for kinase inhibitor to treat cancer patients. AVEO Oncology was successful in getting FDA approval and clearance in June 2020, for the discovery and development of a new drug tivozanib for refractory renal cell disruption and carcinoma. Glaxo Smith Kline PLC joined hands with TESARO Inc. in the January of 2019 to pipeline and expand the study of oncology and see if it fits to provide commercial revenue to the EMEA Cancer biological therapy market.

Report Overview:

The EMEA Cancer biological therapy market provides a statistical and logical analysis of the market growth and the factors leading to it. The report also addresses the opportunities leading to an increasing EMEA Cancer biological therapy industry by analyzing the supply chain from public and private sectors and the developments made by the R&D department in the cancer region. Globally speaking North America, Europe, China, Japan, and the Middle East are highly invested in the EMEA Cancer biological therapy industryto maintain the growth of the world’s healthcare center. The report provides a brief insight into the strategic alliances between the public and private sectors for the cancer biological therapy industry.